Trial · NCT04884763
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Brief Pain Inventory (BPI) Pain Severity at 20 Weeks | 20 weeks. | Assessment of pain severity using the Brief Pain Inventory (BPI) 4-item pain severity scale at 20 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (secondary outcome). |
| Secondary | Brief Pain Inventory (BPI) Pain Interference at 20 Weeks | 20 weeks | Assessment of pain interference using the Brief Pain Inventory (BPI) 7-item pain intensity scale at 20 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | Average Daily Reported Pain Scores at 20 Weeks | 20 weeks | Assessment of pain using average of daily reported pain scores at 20 weeks; average of daily reported scores from days \> week 16 and \<= week 20. Pain scale: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | % of Days Taking Medication for Pain at 20 Weeks | 20 weeks | Assessment of pain using the % of days taking medication for pain at 20 weeks; percentage of days calculated from days \> week 16 and \<= week 20.Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | Pain Improvement Using the Patient Global Impression of Change in Pain at 20 Weeks | 20 weeks | Assessment of pain improvement using the patient global impression of change in pain scale at 20 weeks: 1 (Better) - 7 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | Jaw Function Limitation Scale (JFLS-8) at 20 Weeks | 20 weeks | Jaw Function Limitation Scale (JFLS-8) at 20 weeks: 0 (Better) - 10 (Worse).Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | Patient Health Questionnaire (PHQ-4) at 20 Weeks | 20 weeks | Depressive and Anxiety symptoms using Patient Health Questionnaire (PHQ-4) at 20 weeks: 0 (Better) - 12 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | Somatic Symptoms Scale (SSS-8) at 20 Weeks | 20 weeks | Assessment of somatic symptoms using the Somatic Symptoms Scale (SSS-8) at 20 weeks: 0 (Better) - 32 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome). |
| Secondary | Brief Pain Inventory (BPI) Pain Severity at 24 Weeks | 24 weeks. | Assessment of pain severity using the Brief Pain Inventory (BPI) 4-item pain severity scale at 24 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (primary outcome). |
| Secondary | Brief Pain Inventory (BPI) Pain Interference at 24 Weeks | 24 weeks | Assessment of pain interference using the Brief Pain Inventory (BPI) 7-item pain intensity scale at 24 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
| Secondary | Average Daily Reported Pain Scores at 24 Weeks | 24 weeks | Assessment of pain using average of daily reported pain scores at 24 weeks; average of daily reported scores from days \> week 20 and \<= week 24. Pain scale: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
| Secondary | % of Days Taking Medication for Pain at 24 Weeks | 24 weeks | Assessment of pain using the % of days taking medication for pain at 24 weeks; percentage of days calculated from days \> week 20 and \<= week 24. Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
| Secondary | Pain Improvement Using the Patient Global Impression of Change in Pain at 24 Weeks | 24 weeks | Assessment of pain improvement using the patient global impression of change in pain scale at 24 weeks: 1 (Better) - 7 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
| Secondary | Jaw Function Limitation Scale (JFLS-8) at 24 Weeks | 24 weeks | Jaw Function Limitation Scale (JFLS-8) at 24 weeks: 0 (Better) - 10 (Worse).Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
| Secondary | Patient Health Questionnaire (PHQ-4) at 24 Weeks | 24 weeks | Depressive and Anxiety symptoms using Patient Health Questionnaire (PHQ-4) at 24 weeks: 0 (Better) - 12 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
| Secondary | Somatic Symptoms Scale (SSS-8) at 24 Weeks | 24 weeks | Assessment of somatic symptoms using the Somatic Symptoms Scale (SSS-8) at 24 weeks: 0 (Better) - 32 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04884763/registered